Clinical Trial Update: Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants [Phase 3]

View source ↗

Summary

Open-label Phase 3 safety study of Acoramidis (AG10) in symptomatic transthyretin amyloid cardiomyopathy participants; the trial is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Acoramidis (acoramidis)

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Amyloid Cardiomyopathy, Transthyretin-Related | Phase 3 | Status: ACTIVE_NOT_RECRUITING